Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers
Autor: | Jaume Alijotas‐Reig, Victor García‐GImenez, Peter J. Velthuis, Frank B. Niessen, Tom S. Decates |
---|---|
Přispěvatelé: | Institut Català de la Salut, [Alijotas-Reig J] Unitat de Malalties Autoimmunes Sistèmiques, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [García-GImenez V] Europe Medical Centre, Barcelona, Spain. Sociedad Española de Medicina y Cirugía Cosmética, Barcelona, Spain. [Velthuis PJ, Decates TS] Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands. [Niessen FB] Department of Plastic Surgery, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands, Vall d'Hebron Barcelona Hospital Campus, Dermatology, Plastic, Reconstructive and Hand Surgery, AII - Inflammatory diseases, AMS - Tissue Function & Regeneration |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Inflammation
acciones y usos químicos::usos especializados de productos químicos::materiales biomédicos y dentales::rellenos dérmicos [COMPUESTOS QUÍMICOS Y DROGAS] Vaccines COVID-19 Vaccines Complex Mixtures::Biological Products::Vaccines [CHEMICALS AND DRUGS] SARS-CoV-2 Medicaments - Efectes secundaris COVID-19 Soft tissue fillers Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] Dermatology Pathological Conditions Signs and Symptoms::Pathologic Processes::Inflammation [DISEASES] Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] Inflamació Injections SDG 3 - Good Health and Well-being Dermal Fillers Other subheadings::Other subheadings::/adverse effects [Other subheadings] afecciones patológicas signos y síntomas::procesos patológicos::inflamación [ENFERMEDADES] virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] Humans Adverse reactions Chemical Actions and Uses::Specialty Uses of Chemicals::Biomedical and Dental Materials::Dermal Fillers [CHEMICALS AND DRUGS] COVID-19 (Malaltia) - Vacunació mezclas complejas::productos biológicos::vacunas [COMPUESTOS QUÍMICOS Y DROGAS] |
Zdroj: | Scientia Journal of Cosmetic Dermatology, 21(8), 3181-3187. Wiley-Blackwell Publishing Ltd Alijotas-Reig, J, García-GImenez, V, Velthuis, P J, Niessen, F B & Decates, T S 2022, ' Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers : A case series of 20 patients ', Journal of Cosmetic Dermatology, vol. 21, no. 8, pp. 3181-3187 . https://doi.org/10.1111/jocd.15117 Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona |
ISSN: | 1473-2165 1473-2130 |
Popis: | COVID-19; Inflammation; Soft tissue fillers COVID-19; Inflamación; Rellenos de tejidos blandos COVID-19; Inflamació; Farciments de teixits tous Background Adverse events (AE) after COVID-19 vaccines, particularly, but not solely, with those messenger RNA (mRNA)-based vaccines, have rarely been reported in patients previously treated with dermal fillers (DF). Objective To evaluate the morphology, clinical characteristics, the timing of presentation, and outcomes of inflammatory AE appeared in patients injected with DF, after anti-COVID-19 vaccination. Methods Descriptive study of a case series of 20 consecutive patients collected after the occurrence of AE in previously filled areas post COVID-19 vaccination. Results From January 2021 to July 2021, we analyzed 20 AE reactions triggered by COVID-19 vaccines in the previously mentioned cohort. They were vaccinated with Pfizer/Biontech (11; 55%), Moderna (5; 25%), Astra-Zeneca (3; 15%), and Sputnik (1; 5%). The most common manifestations were oedema/swelling, angioedema, erythema, skin induration, and granuloma. Less common reactions included myalgia and lymphadenopathy. In 13/20 (65%) cases, the AE appeared after the first dose of vaccine. These inflammatory AE appeared more rapidly after the second dose than after the first one. In 13/20 (65%) cases, the symptomatology subsided with anti-inflammatory/antihistaminic drugs, while spontaneously in 3/20 (15%). The manifestations are ongoing.in the remaining four cases (20%). Conclusion Although probably rare, both RNA-based and adenovirus-based anti-COVID-19 vaccines can cause inflammatory bouts in patients previously treated with DF. In these cases, caution should be paid on subsequent vaccine doses, considering a tailored risk/benefit for any case before next vaccination. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |